Docetaxel (Taxotere®) plus cisplatin:: an active and well-tolerated combination in patients with advanced non-small cell lung cancer
Docetaxel (Taxotere®) plus cisplatin:: an active and well-tolerated combination in patients with advanced non-small cell lung cancer
复制标题
DOI：
10.1016/s0959-8049(98)00287-1
复制
发表时间：
1998-12-01
影响因子：
8.4
通讯作者：
Bérille, J
中科院分区：
文献类型：
--
作者：
Le Chevalier, T;Monnier, A;Bérille, J
在51例未经化疗的局部晚期或转移性非小细胞肺癌（NSCLC）患者中，研究了多西他赛75 mg/m2静脉给药联合顺铂10 mg/m2每3周一次，共3个周期，然后每6周一次的活性。该人群92%为男性，中位年龄为54岁，中位体能状态为1; 80%的患者患有转移性疾病，包括37%的骨受累患者。所有患者均接受预防性术前用药（昂丹司琼，地塞米松加西替利嗪）和标准的水化过度。中位治疗周期为4个（范围1-9），42例可评价患者中有14例缓解（总缓解率33.3%，95%CI 19.6-49.6%）;中位缓解持续时间为7.3个月，中位生存期为8.4个月，1年生存率为35%。最常见的不良事件是中性粒细胞减少症，发生在三分之二的患者中。神经感觉效应是累积性的，但通常是轻度的。未发生给药相关死亡。这种多西他赛/顺铂联合治疗在晚期NSCLC中显示出活性，虽然它并不明显上级多西他赛单药治疗，但由于开放试验中患者预后因素的差异，需要进行一项随机研究来明确证明顺铂是否增加了多西他赛的活性。(C)1998爱思唯尔科技有限公司版权所有。
The activity of the combination of intravenous docetaxel 75 mg/m(2) plus cisplatin 10 mg/m(2) administered every 3 weeks for 3 cycles then every 6 weeks was investigated in 51 chemotherapy naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The population was 92% male, with a median age of 54 years and median performance status of 1; 80% of patients had metastatic disease, including 37% with hone involvement. All patients received prophylactic premedication (ondansetron, dexamethasone plus cetirizine) and standard hyperhydration. With a median of 4 treatment cycles (range 1-9), 14 of 42 evaluable patients responded (overall response rate 33.3%, 95% CI 19.6-49.6%); the median response duration was 7.3 months, median survival 8.4 months, and 1-year survival rate 35%. The most common adverse event was neutropenia, occurring in two-thirds of patients. Neurosensory effects were cumulative hut generally mild. No treatment-related deaths occurred. This combination of docetaxel/cisplatin showed activity in advanced NSCLC, While it was not clearly superior to single-agent docetaxel, due to differences in prognostic factors among the patients in open trials, a randomised study would he needed to demonstrate definitively whether cisplatin adds to the activity of docetaxel or not. (C) 1998 Elsevier Science Ltd. All rights reserved.